Nathalie Van den Haute

Nathalie Van den Haute

Nathalie Van den Haute

Executive Director Corporate Finance - KBC Securities

In 2005, Nathalie joined the Corporate Finance department of KBC Securities, after obtaining a Masters in Financial Management at the Vlerick Management School. In 2004, she graduated as a Commercial Engineer at the University of Brussels - Solvay Management School. Over the past years, Nathalie has been involved in several ECM and M&A transactions and has developed a close affinity with the biotech and pharma sector through transactions such as the IPO of Movetis and the SPO and ABO of Ablynx. Other selected ECM transaction experience includes the IPOs of bpost, Nyrstar and Metris and the rights issues of Elia and Agfa-Gevaert. Nathalie’s M&A transaction experience includes both sell-side mandates (a.o. the entry of Sofindev in the share capital of Vanerum Group and the sale of a 30% stake in Siat to a consortium of renowned international investors) and buy-side mandates (a.o. the acquisition of SBS Belgium by the consortium De Vijver/Corelio/Sanoma, the acquisition of PCM Algemene Uitgeverijen by WPG and Uitgeverij Lannoo and the cross-border acquisition of the German SAV group by Indaver). Nathalie has worked also on several valuation assignments (Elia, Siat, etc.) and independent expert reports (Electrabel, Omega Pharma).

Flanders.bio Strategic Partners

Flanders.bio Supporting Partners